Crescent Biopharma () 2025 Conference Transcript

Summary of Crescent Biopharma Conference Call Company Overview - Company: Crescent Biopharma - Focus: Building a leading biotech oncology franchise with a dual strategy involving bispecific antibodies and antibody-drug conjugates (ADCs) [2][3] Key Points Business Strategy - Crescent Biopharma aims to develop a VEGF/PD-1 bispecific antibody (CR-001) and a portfolio of ADCs [3][4] - The company went public through a reverse merger, which has provided broader access to capital and visibility in the market [4][5] - The cash runway is projected to last through 2027, allowing the company to fund initial phase one data generation [7] Product Development - CR-001 is expected to enter the clinic in early Q1 2024, with data anticipated by Q4 2026 or Q1 2027 [7][8] - The first ADC is planned to enter the clinic by mid-2026 [7] - The company is focused on solid tumor indications, aiming to improve patient outcomes [3][7] Competitive Landscape - The bispecific antibody class, particularly CR-001, is positioned to compete with existing PD-1 and VEGF inhibitors, with a focus on indications where these have previously failed [12][24] - Crescent Biopharma is closely monitoring data from competitors, including IBI-NSCEMAB, to inform its development strategy [24][25] Clinical Development - The phase one trial for CR-001 will focus on safety, tolerability, pharmacokinetics, and anti-tumor activity [32][33] - The study will be global, including sites in the U.S. and Europe, to gather diverse population data [37][39] - Specific tumor types of interest include thoracic, gastrointestinal, and gynecological cancers [43][44] Future Directions - The company is considering partnerships but believes it can compete independently due to its dual business strategy [50][51] - ADC development is ongoing, with plans to disclose targets in the future, focusing on known targets rather than novel ones initially [52][56] - Crescent Biopharma aims to differentiate its ADCs through innovative strategies while minimizing risk [57][58] Additional Insights - The management emphasizes the importance of regulatory discussions to optimize the development timeline and dosing strategies [34][35] - The company is committed to transparency and maintaining a dialogue with investors as it progresses through clinical trials [4][5] This summary encapsulates the key aspects of Crescent Biopharma's strategy, product development, and competitive positioning as discussed in the conference call.